Accessibility Menu
Synairgen Plc logo

Synairgen Plc(OTC) SYGGF

Current Price$0.00
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-100%
1 Year-67%
1 Month+0%
Synairgen Plc last closing stock price
MetricPriceDate
Last closeUSD 0.002026-06-30
Synairgen Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-03-09
1 month+0%USD 0.002026-03-09
3 month+0%USD 0.002026-03-09
Year to date+9,900%USD 0.002025-12-30
1 year-66.67%USD 0.002025-06-27
3 year-99.89%USD 0.092023-06-30
5 year-100%USD 2.332021-07-01
Since inception-100%USD 2.512020-07-20

Synairgen Plc Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£0.00

Net Income (TTM)

-£15.22M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-1.13 (Low)

Price

$0.00

Volume

68

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Sep 24, 2026

SYGGF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Synairgen Plc

Synairgen plc is a biopharmaceutical company dedicated to developing innovative therapeutic drugs for respiratory conditions. The company is advancing its product pipeline, which includes SNG001, an inhaled interferon beta for COVID-19 treatment, and a LOXL2 inhibitor for idiopathic pulmonary fibrosis.

Products and Services
  • SNG001: Inhaled interferon beta for COVID-19 treatment
  • Inhaled formulation of interferon beta for asthma and COPD
  • LOXL2 inhibitor for idiopathic pulmonary fibrosis
Growth Outlook
  • Strong focus on respiratory diseases with significant unmet needs
  • Ongoing Phase II trials for multiple product candidates
  • Potential for strategic partnerships to enhance development capabilities
Financial Highlights
  • Recent quarterly net income of -£3.55 million, reflecting ongoing R&D investments
  • Cash and cash equivalents of £4.55 million as of Q4 2024
  • Current ratio of 9.01 indicates strong liquidity position
Synairgen plc is positioned in the biotechnology sector, focusing on respiratory conditions that affect millions globally. The company's innovative approach to drug development, particularly with SNG001, highlights its commitment to addressing urgent health challenges. The ongoing clinical trials and potential for partnerships suggest a promising trajectory for growth. Financially, while the company is currently operating at a loss, it maintains a robust liquidity position, which is crucial for funding its research and development efforts. The focus on unmet medical needs in respiratory diseases may attract investor interest as the company progresses through its clinical trials and seeks to bring its products to market.
AI Generated • Jul 8, 2026

Industry

Biotechnology

Employees

34

CEO

Richard James Marsden

Headquarters

Southampton, LO SO16 6YD, GB

SYGGF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-51.06%

Return on Capital

-132.59%

Return on Assets

-59.12%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

68

Avg. Volume

1.097

Financials (TTM)

Gross Profit

-£125.47K

Operating Income

-£18.62M

EBITDA

-£15.77M

Operating Cash Flow

-£16.03M

Capital Expenditure

-£107.27K

Free Cash Flow

-£16.14M

Cash & ST Invst.

£4.55M

Total Debt

£0.00

Synairgen Plc Performance Analysis

Synairgen Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31GBP 0N/A
20222022-12-31GBP 0N/A
20232023-12-31GBP 0N/A
20242024-12-31GBP 0N/A
Synairgen Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-30N/A
Q42023-12-31N/A
Q22024-06-30N/A
Q42024-12-31N/A
Synairgen Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31GBP -0.33N/A
20222022-12-31GBP -0.11-67.7%
20232023-12-31GBP -0.05-51.9%
20242024-12-31GBP -0.04-16.8%
Synairgen Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-309.2%
Q42023-12-3122.9%
Q22024-06-3011.0%
Q42024-12-31-8.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

£0.00

N/A

Gross Profit

-£23.77K

+52.5%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

34

N/A

Net Income

-£3.55M

+32.3%

EBITDA

-£4.40M

-40.9%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

£4.55M

-76.9%

Total Debt

£0.00

N/A

Accounts Receivable

£0.00

N/A

Inventory

£0.00

+100.0%

Long Term Debt

£0.00

N/A

Short Term Debt

£0.00

N/A

Return on Assets

-59.12%

N/A

Return on Invested Capital

-81.31%

N/A

Free Cash Flow

-£4.22M

-354.8%

Operating Cash Flow

-£4.12M

-348.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLCSCell Source, Inc.
$0.80+0.00%
ZHCLFZenith Capital Corp.
$0.05+0.00%
PPCBPropanc Biopharma, Inc.
$1.44+4.35%
TELIFTelescope Innovations Corp.
$0.31+1.79%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%

Questions About SYGGF

What is the current price of Synairgen Plc?

Synairgen Plc is trading at $0.00 per share.

What is the 52-week range for Synairgen Plc?

Over the past 52 weeks, Synairgen Plc has traded between $0.00 and $0.00.

How much debt does Synairgen Plc have?

As of the most recent reporting period, Synairgen Plc reported total debt of £0.00.

How much cash does Synairgen Plc have on hand?

Synairgen Plc reported £5.70M in cash and cash equivalents in its most recent financial results.

What is Synairgen Plc’s dividend yield?

Synairgen Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.